Moderna’s Once-Rebuffed mRNA Flu Shot to Face Scrutiny From FDA Adcomm

Why It Matters

The review will determine whether the first mRNA flu shot reaches the U.S. market, potentially reshaping seasonal vaccine strategies and setting a precedent for future mRNA applications. It also reflects how regulatory turbulence can affect drug timelines and investor confidence.

Key Takeaways

• FDA advisory panel meets June 18 to review Moderna's mRNA flu vaccine
• Initial refusal cited lack of CDC‑recommended vaccine comparator
• Compromise allows regular approval for ages 50‑64, accelerated for 65+
• Leadership turnover at FDA's CBER and CDER intensifies regulatory uncertainty
• Decision expected in August, impacting U.S. flu vaccine market

Pulse Analysis

Moderna’s MFLUSIVA represents the biotech industry’s push to translate mRNA technology, proven by COVID‑19 vaccines, into seasonal influenza protection. By targeting adults over 50, the candidate could address a demographic that bears the highest flu‑related morbidity and mortality. The FDA’s advisory committee meeting on June 18 will scrutinize safety and efficacy data, a critical step before the agency can grant either regular or accelerated approval, the latter reserved for high‑need populations.

The regulatory journey has been anything but smooth. In February, the FDA rejected Moderna’s filing, citing a trial design that omitted a CDC‑recommended flu vaccine comparator, a breach of guidance issued in 2024. The decision sparked political backlash, prompted investigations into senior FDA officials, and led to a cascade of resignations, including the agency’s chief of staff and AI officer. After negotiations, the FDA agreed to accept a revised application, signaling a rare compromise amid heightened scrutiny of the agency’s processes.

If approved, MFLUSIVA could disrupt the U.S. flu vaccine market, which currently relies on egg‑based vaccines with variable efficacy. An mRNA platform promises faster production cycles and potentially broader strain coverage, aligning with public health goals to improve seasonal flu outcomes. Stakeholders—investors, healthcare providers, and policymakers—should monitor the August decision timeline, as it will influence supply chain planning, reimbursement negotiations, and future mRNA vaccine development pathways.